Peter Ellmark

1.8k total citations
62 papers, 1.3k citations indexed

About

Peter Ellmark is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Peter Ellmark has authored 62 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Immunology, 37 papers in Oncology and 29 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Peter Ellmark's work include Monoclonal and Polyclonal Antibodies Research (29 papers), CAR-T cell therapy research (27 papers) and Cancer Immunotherapy and Biomarkers (27 papers). Peter Ellmark is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (29 papers), CAR-T cell therapy research (27 papers) and Cancer Immunotherapy and Biomarkers (27 papers). Peter Ellmark collaborates with scholars based in Sweden, United States and France. Peter Ellmark's co-authors include Carl Borrebaeck, Sara M. Mangsbo, Thomas H. Tötterman, Christer Wingren, Johan Ingvarsson, Anders Carlsson, Per Norlén, Christina Furebring, Linda C. Sandin and Niina Veitonmäki and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Peter Ellmark

58 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Ellmark Sweden 18 610 598 492 342 218 62 1.3k
Ulrike Köhl Germany 23 593 1.0× 593 1.0× 356 0.7× 81 0.2× 100 0.5× 61 1.3k
Shangzi Wang United States 10 480 0.8× 502 0.8× 522 1.1× 445 1.3× 145 0.7× 16 1.2k
Israt S. Alam United States 22 413 0.7× 535 0.9× 360 0.7× 280 0.8× 371 1.7× 44 1.3k
Luke Cassereau United States 7 229 0.4× 666 1.1× 664 1.3× 101 0.3× 602 2.8× 8 1.9k
Meritxell Balmaña Portugal 16 402 0.7× 172 0.3× 903 1.8× 106 0.3× 70 0.3× 21 1.1k
Felix B. Salazar United States 18 605 1.0× 700 1.2× 371 0.8× 471 1.4× 516 2.4× 29 1.6k
Shahriar Yaghoubi United States 18 343 0.6× 625 1.0× 544 1.1× 370 1.1× 343 1.6× 30 1.6k
Fiona E. Smyth Australia 23 261 0.4× 625 1.0× 526 1.1× 622 1.8× 93 0.4× 39 1.3k
Leonie E. Paulis Netherlands 19 289 0.5× 167 0.3× 260 0.5× 384 1.1× 304 1.4× 26 1.0k
Kristin L.M. Boylan United States 17 329 0.5× 416 0.7× 375 0.8× 45 0.1× 69 0.3× 28 1.0k

Countries citing papers authored by Peter Ellmark

Since Specialization
Citations

This map shows the geographic impact of Peter Ellmark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Ellmark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Ellmark more than expected).

Fields of papers citing papers by Peter Ellmark

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Ellmark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Ellmark. The network helps show where Peter Ellmark may publish in the future.

Co-authorship network of co-authors of Peter Ellmark

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Ellmark. A scholar is included among the top collaborators of Peter Ellmark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Ellmark. Peter Ellmark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Hägerbrand, Karin, et al.. (2024). Next-generation CD40 agonists for cancer immunotherapy. Expert Opinion on Biological Therapy. 24(5). 351–363. 8 indexed citations
3.
Laethem, Jean–Luc Van, Ivan Borbath, Hans Prenen, et al.. (2024). Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study. The Lancet Oncology. 25(7). 853–864. 23 indexed citations
4.
5.
6.
Georganaki, Maria, Mohanraj Ramachandran, Nicolás Gonzalo Núñez, et al.. (2020). Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy. OncoImmunology. 9(1). 1730538–1730538. 33 indexed citations
7.
Kvarnhammar, Anne Månsson, Niina Veitonmäki, Karin Hägerbrand, et al.. (2019). The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. Journal for ImmunoTherapy of Cancer. 7(1). 103–103. 89 indexed citations
8.
Misher, Lynda, David Bienvenue, Sara Fritzell, et al.. (2018). Activation of the CD137 Pathway in T cells by a CD137 × 5T4 bispecific ADAPTIR Molecule Requires Co-engagement of CD137 and 5T4. The Journal of Immunology. 200(Supplement_1). 58.21–58.21. 1 indexed citations
9.
Ellmark, Peter, Sara M. Mangsbo, Christina Furebring, Per Norlén, & Thomas H. Tötterman. (2016). Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation. Cancer Immunology Immunotherapy. 66(1). 1–7. 35 indexed citations
10.
Ellmark, Peter, Sara M. Mangsbo, Christina Furebring, Thomas H. Tötterman, & Per Norlén. (2015). Kick-starting the cancer-immunity cycle by targeting CD40. OncoImmunology. 4(7). e1011484–e1011484. 16 indexed citations
11.
Mangsbo, Sara M., Niina Veitonmäki, Christina Furebring, et al.. (2014). The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity. Clinical Cancer Research. 21(5). 1115–1126. 84 indexed citations
12.
Sandin, Linda C., Anna Orlova, Erika Gustafsson, et al.. (2013). Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer. Cancer Immunology Research. 2(1). 80–90. 81 indexed citations
13.
Abayneh, Sisay, Peter Ellmark, U. O. Karlsson, et al.. (2008). Sensitivity of HIV Type 1 Primary Isolates to Human Anti-CD40 Antibody-Mediated Suppression Is Related to Coreceptor Use. AIDS Research and Human Retroviruses. 24(3). 447–452. 3 indexed citations
14.
Ellmark, Peter, et al.. (2008). Identification of a Strongly Activating Human Anti-CD40 Antibody That Suppresses HIV Type 1 Infection. AIDS Research and Human Retroviruses. 24(3). 367–373. 7 indexed citations
15.
Ingvarsson, Johan, Christer Wingren, Anders Carlsson, et al.. (2008). Detection of pancreatic cancer using antibody microarray‐based serum protein profiling. PROTEOMICS. 8(11). 2211–2219. 96 indexed citations
16.
Carlsson, Anders, Christer Wingren, Johan Ingvarsson, et al.. (2008). Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays. European Journal of Cancer. 44(3). 472–480. 95 indexed citations
17.
Sekula, S. T., Susanne Weg‐Remers, Peter Nagel, et al.. (2008). Multiplexed Lipid Dip‐Pen Nanolithography on Subcellular Scales for the Templating of Functional Proteins and Cell Culture. Small. 4(10). 1785–1793. 119 indexed citations
18.
Ingvarsson, Johan, Jenny Karlsson, Peter Ellmark, et al.. (2006). High-throughput membrane proteomics using recombinant antibody microarrays. Molecular & Cellular Proteomics. 5(10). 70–70. 2 indexed citations
19.
Ellmark, Peter, Larissa Belov, Pauline Huang, et al.. (2006). Multiplex detection of surface molecules on colorectal cancers. PROTEOMICS. 6(6). 1791–1802. 51 indexed citations
20.
Ellmark, Peter, Mats Ohlin, Carl Borrebaeck, & Christina Furebring. (2004). A novel mammalian display system for the selection of protein–protein interactions by decoy receptor engagement. Journal of Molecular Recognition. 17(4). 316–322. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ulrike Köhl Breakdown of academic impact, for papers by Shangzi Wang Breakdown of academic impact, for papers by Israt S. Alam Breakdown of academic impact, for papers by Luke Cassereau Breakdown of academic impact, for papers by Meritxell Balmaña Breakdown of academic impact, for papers by Felix B. Salazar Breakdown of academic impact, for papers by Shahriar Yaghoubi Breakdown of academic impact, for papers by Fiona E. Smyth Breakdown of academic impact, for papers by Leonie E. Paulis Breakdown of academic impact, for papers by Kristin L.M. Boylan
Rankless by CCL
2026